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Abstract
Background: It has long been appreciated that different subtypes (serous, clear cell, endometrioid and mucinous)
of epithelial ovarian carcinoma (EOC) have distinct pathogenetic pathways. However, clinical management,
especially chemotherapeutic regimens, for EOC patients is not subtype specific. Ovarian clear cell carcinoma
(CCC) is a rare histological subtype of EOC, which exhibits high rates of recurrence and low chemosensitivity.
We assessed potential therapeutic targets for ovarian CCC patients through analyzing the variation of drug-based
molecular biomarkers expression between ovarian CCC and high-grade serous carcinoma (HGSC).
Methods: Seven candidate drug-based molecular biomarkers, human epidermal growth factor receptor (EGFR), human
epidermal growth factor receptor-2 (HER2), phosphatase and tensin homolog deleted on chromosome ten (PTEN),
aurora kinase A (AURKA), breast cancer susceptibility gene 1 (BRCA1), breast cancer susceptibility gene 2 (BRCA2) and
programmed death-ligand 1 (PD-L1) were measured in 96 ovarian CCC and 113 HGSC by immunohistochemistry in
paraffin embedded tissues. The relationship between these biomarkers and clinicopathological factors were explored.
Results: The expression level of four of the seven drug-based molecular biomarkers was markedly different between
HGSC and CCC. High expression levels of HER2 and PD-L1 were more commonly observed in CCC patients (12.6% vs 2.
7%, 21.1% vs 11.6%, P = 0.006, 0.064, respectively), while loss of BRCA1 and BRCA2 expression were more frequently
occurred in HGSC patients (72.6% vs 54.3%, 89.4% vs 79.8%, P = 0.007, 0.054, respectively). Survival analysis showed that
five of seven biomarkers had prognostic values but varied between subtypes. Furthermore, EGFR expressed frequently
in CCC patients with endometriosis than in HGSC patients (44.4% vs 8.3%, P = 0.049). AURKA and PD-L1 correlated with
the resistance to platinum-based chemotherapy in CCC patients (P = 0.043, 0.028, respectively) while no similar results
were observed in HGSC patients.
Conclusion: Ovarian CCC showed a markedly different expression map of drug-based molecular biomarkers from
HGSC, which suggested a new personalized target therapy in this rare subtype.
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Background
The histological types of epithelial ovarian carcinoma
(EOC) have distinct clinical and molecular features with
each other [1, 2]. To date, EOC patients are mostly pro-
vided with the same therapeutic regimens regardless of
the distinct histological characteristics of the primary
lesion [3]. However, ovarian clear cell carcinoma (CCC),
contributing for 4.8–25% of all ovarian carcinomas [4],
is known to be less sensitive to platinum-based front-
line chemotherapy and to be associated with a poorer
prognosis than the more common serous subtype.
Moreover, previous studies have shown that the
response rate of various second-line chemotherapeutic
regimens for recurrent platinum-resistant ovarian CCC
was only 1% [5]. Therefore, a further investigation of
the mechanism of the chemoresistance and developing
new therapeutic targets are needed for effective clinical
management of ovarian CCC.
Although the mechanism of carcinogenesis and che-
moresistance of ovarian CCC is still unclear, several
genetic changes have been widely investigated. Compared
with ovarian high-grade serous carcinomas (HGSC), ovar-
ian CCC are generally negative for p53 mutation and have
a lower frequency (6.3%) of breast cancer 1 or 2 (BRCA1/
2) mutations [6, 7]. A higher frequency of AT rich inter-
active domain 1A (ARID1A) and phosphatidylinositol-4,
5-bisphosphate 3-kinase catalytic subunit α (PIK3CA) mu-
tations (36%) were also observed in CCC patients [8, 9].
In addition, protein expression studies of ovarian
CCC observed five functional protein activating path-
ways [10], some of which could be potential therapeutic
targets: (PI3K)/AKT/mammalian target of rapamycin
(mTOR) pathway, hypoxia-inducible factor 1α (HIF-1α)/
vascular endothelial growth factor (VEGF) pathway,
hepatocyte nuclear factor 1β (HNF-1β) pathway, inter-
leukin 6 (IL-6)/signal transducer and activator of tran-
scription 3 (STAT3) pathway and MET pathway [11–15].
Recently, Sereni et al. detected 117 drug-based protein ex-
pression levels of 72 EOC patients by using reverse-phase
protein microarray (RPPA) analysis. They found that 11
out of 117 proteins of ovarian CCC (n = 7) showed a
distinct signaling network from other subtypes of EOC,
such as enhanced activation of phosphorylated epider-
mal growth factor receptor (EGFR) and phosphorylated
human epidermal growth factor receptor-2 (HER2)
[16]. However, the sample size of ovarian CCC in the
study of Sereni et al. was not large enough due to the
rarity of this subtype. In the current study, we simul-
taneously compared seven drug-based protein expres-
sion levels (either in an existing FDA-approved therapy
or in an experimental therapeutic in clinical trial) both
in ovarian CCC and HGSC on a larger scale and inves-




This study was approved by the Institutional Review
Board of Fudan University Shanghai Cancer Center
(FUSCC). A written informed consent was obtained from
all recruited individuals, and each clinical investigation
was conducted according to the principles expressed in
the Declaration of Helsinki consent. 96 primary ovarian
CCC cases and 113 primary HGSC cases from FUSCC
were randomly selected between January 2008 and
December 2015. Data collection included age at diagno-
sis, International Federation of Gynecology and Obstetrics
(FIGO) stage, residual disease (optimal debulking <1 cm),
ascites, endometriosis and chemotherapeutic regimens.
Primary patients with early stage (I and II) underwent
complete staging surgery and patients with late stage (III
and IV) received cytoreductive surgery. The majority of
the patients received platinum-based chemotherapy regi-
mens after primary surgery, and patients were followed up
every 3 months for the first year, every 6 months for the
next 4 years, and annually for the following years there-
after. Progression-free survival (PFS) and overall survival
(OS) duration were calculated from the date of first sur-
gery to the date of disease recurrence and death or the last
follow-up visit, respectively.
Tissue microarray (TMA) and Immunohistochemistry (IHC)
The portions of tumor tissue to be used for the tissue
microarray were selected from a representative tumor
area in the corresponding H&E stained section of each
block by two gynecologic pathologists (R B and XY T).
A 10 ×12 (120 cores) array was made by the Tissue Bank
of FUSCC. Each case has two cores made from separate
sources. IHC was performed on 5-μm-thick TMA sections
from formalin-fixed, paraffin-embedded tissues. Immuno-
histochemical staining of EGFR, HER2/neu, PTEN and
PD-L1 were run through an automated protocol including
heat antigen retrieval (Ventana System). AURKA, BRCA1
and BRCA2 were performed as the following. Briefly,
xylene dewaxed and alcohol-rehydrated TMA slides
were treated in 10 mM citrate buffer (PH = 6.0) at 100 °C
for 10 min, according to the antigen retrieval method.
After cooling for 2 h, endogenous peroxidase activity was
blocked with 3% hydrogen peroxide solution. Then
nonspecific binding was inhibited with nonimmune
goat serum (Maixin Biological Technology Development,
Fuzhou, China) for 30 min. Antibodies against molecular
biomarkers, BRCA1, BRCA2 and AURKA (see Additional
file 1: Table S1) were incubated on the tumor tissues for
14 h at 4 °C in a moist chamber, which were followed by a
secondary incubation with pre-diluted anti-rabbit HRP for
1 h (Maixin Biological Technology Development, Fuzhou,
China). Molecular biomarker signals were visualized after
addition of 3, 3’-diaminobenzidine tetrahydrochloride
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(DAB) for the dilution of 1:50. TMA slides counter-
staining was performed with hematoxylin. The positive
controls are known positive case samples. And nonim-
mune goat serum takes the place of primary antibody
serving as the negative control.
TMA scoring
The IHC staining results were scored independently by
two gynecologic pathologists (R B and XY T), who were
blinded to clinical information of the patients. Scoring sys-
tem is on the basis of both percentage of positive tumor
cells and staining intensity. Staining intensity was graded
0 (none), 1 (weak), 2 (intermediate) or 3 (strong), and dis-
tribution of the cellular staining was graded as 0 (none),1
(<10% of the cells), 2 (11%–50% of the cells), 3 (51%–75%
of the cells) or 4 (>75% of the cells). The multiplication of
intensity and distribution was scored 0 (≦3), 1+ (>3 to 6),
2+ (>6 to 9), or 3+ (>9 to 12). Finally, the assessment of
the protein expression was defined as negative (<2+) and
positive (≧2+ to 3+). Both of cytoplasmic and nuclear
positive cores of AURKA were defined as positive. For
cores that were uninterpretable caused by tissue loss or
lacking of tumor cells, a score of not applicable (N/A) was
assigned.
Statistical analysis
SPSS 19.0 software (IBM, Armonk, New York, USA) was
used for the analysis. We performed Kaplan–Meier Model
and multivariate Cox proportional hazards regression
analysis for survival estimate. Chi-squared test was used to
detect the association of molecular biomarker expression
level with clinicopathological factors. Each reported P value
was two sided, and P < 0.05 was used to infer statistical
significance.
Results
Study of the patient cohort
Clinicopathological characteristics of the ovarian HGSC and
CCC patients enrolled in the study were summarized in
Tables 1 and 2. The median follow-up time was 45.0 months
(range 2.0–90.0) in HGSC and 18.0 months (range 2.0–
91.0) in CCC. There were 84/108 (77.8%, median time
47.0 months) recurrences, 61/113 (54.0%) deaths in HGSC
and 39/91 (42.9%, median time 12.5 months) recurrences,
26/96 (27.1%) deaths in CCC. By using univariate and multi-
variate Cox proportional hazards regression model, we eval-
uated potentially prognostic factors in this two subtypes of
patients. The results revealed that a shorter overall survival
time was associated with late FIGO stage (III + IV) (adjusted
HR 3.241, 95% CI 1.065–10.879, P= 0.047 in HGSC and
Table 1 Clinical prognostic features of HGSC patients
Prognostic factors Cases (%) Univariate Pa Multivariate
HR (95% CI) Pb
Age (years) 0.281 0.495
≤ 57 (median) 57(50.4) 1.000
> 57 (median) 56(49.6) 1.010(0.982–1.037)
FIGO Stage 0.002 0.047
Early(I + II) 17(15.0) 1.000
Late(III + IV) 96(85.0) 3.241(1.065–10.879)
Residual tumor (cm) 0.042 0.543
≤ 1 104(92.0) 1.000







Chemotherapeutic response 0.000 0.000
Platinum sensitive 77(72.0) 1.000
Platinum resistant 30(28.0) 3.573(2.056–6.210)
Log rank test
awithout adjustment
Cox proportional hazards regression analysis
bwith adjustment for age, FIGO stage, residual tumor, ascites, endometriosis, and chemotherapeutic response
Bold value denotes P with statistical significance
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HR 4.660 95% CI 1.533–14.167, P = 0.007 in CCC, Tables 1
and 2) and chemoresistance (adjusted HR 3.573, 95% CI
2.056–6.210, P= 0.000) in HGSC and HR 7.230, 95% CI
1.992–26.237, P= 0.003 in CCC, Tables 1 and 2). Besides,
another two factors in univariate analysis, residual tumor
size >1 cm (P=0.042) and ascites (P= 0.005), also implied
poor prognosis of HGSC and CCC patients, respectively.
Ovarian CCC patients showed different expression map of
drug-based molecular biomarkers from HGSC patients
Typical immunohistochemistry results of the drug-based
molecular biomarkers were partly presented in Fig. 1. The
results showed a significant difference of biomarker expres-
sion map between HGSC and CCC. High levels of HER2
and PD-L1 were commonly observed in CCC patients,
compared with HGSC (12.6% vs 2.7%, 21.1% vs 11.6%, re-
spectively, P = 0.006, 0.064 respectively, Chi-squared test).
Loss of BRCA1 and BRCA2 expression were more fre-
quently occurred in HGSC (72.6% vs 54.3%, 89.4% vs 79.8%,
P = 0.007, 0.054, respectively). In addition, it showed little
difference in positive rates of EGFR, PTEN, and AURKA
between the two subtypes (Fig. 2). We further explored the
association of the expression level of these markers with
PFS/OS in both of the HGSC and CCC patients (Table 3).
According to Kaplan-Meier model, five of seven biomarkers
showed prognostic value in at least one subtype (Fig. 3). For
HGSC patients, we found that poor prognosis were often
companied by high expression levels of EGFR, AURKA
(P = 0.017, 0.006, respectively), while better prognosis were
associated with overexpression of BRCA1 and PD-L1
(P = 0.017, 0.037, respectively). Interestingly, the results of
CCC group exhibited a different biomarker expression
map—high expression level of EGFR had a relationship with
longer survival time (P = 0.012) and overexpression of
HER2 and AURKA predicted shorter survival time and
progression-free time (P =0.001, 0.022, respectively). With
multivariate Cox proportional hazards regression analysis,
we found that CCC patients with late FIGO stage, low ex-
pression of EGFR and high expression of HER2 exhibited
shorter survival time, while HGSC patients with high ex-
pression of AURKA and low expression of BRCA1 had
poorer prognosis (Table 4). Chemoresistance is a strong
negative prognostic factor in both of the two subtypes.
Expression of drug-based molecular biomarkers in ovarian
CCC exhibited various relationships to clinicopathological
factors
We further analyzed the relationship between bio-
markers expression level and clinicopathological factors
(Additional file 1: Table S2A and B). The results showed
Table 2 Clinical prognostic features of CCC patients
Prognostic factors Cases (%) Univariate Multivariate
96(100) Pc HR (95% CI) Pd
Age (years) 0.524 0.292
≤ 54 (median) 50(52.1) 1.000
> 54 (median) 46(47.9) 0.980(0.944–1.017)
FIGO Stage 0.000 0.007
Early(I + II) 64(66.7) 1.000
Late(III + IV) 32(33.3) 4.660(1.533–14.167)
Residual tumor (cm) 0.115 0.541
≤ 1 93(96.9) 1.000







Chemotherapeutic response 0.000 0.003
Platinum sensitive 64(72.7) 1.000
Platinum resistant 24(27.3) 7.230(1.992–26.237)
Log rank test
cwithout adjustment
Cox proportional hazards regression analysis
dwith adjustment for age, FIGO stage, residual tumor, ascites, endometriosis, and chemotherapeutic response
Bold value denotes P with statistical significance
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that HGSC patients with late stage were more likely to
lose PTEN expression (P = 0.036), while CCC patients
have a higher rate of PTEN silence in early stage instead
of late stage (P = 0.283). Since endometriosis plays a cru-
cial part in the carcinogenesis of CCC, we investigated
potential relationship between these biomarkers and
endometriosis. Although no significant results were
observed, CCC patients with endometriosis showed a
higher expression rate of EGFR compared with HGSC
patients (Fig. 4, 44.4% vs 8.3%, P = 0.049). To explore
candidate chemotherapeutic targets, we verified associa-
tions of these biomarkers with chemotherapeutic re-
sponse as well as recurrence status (Chi-squared test,
Table 5 and Additional file 1: Table S3). When the two
different histopathological subgroups were compared, it
was noted that positive AURKA and PD-L1 staining
were observed more frequently in CCC patients with
platinum-based chemotherapeutic resistance (P = 0.042,
0.028, respectively). In addition, as discussed earlier, an-
other striking finding was that EGFR showed a markedly
Fig. 1 Representative immunostains of seven biomarkers in ovarian clear cell carcinoma (x 200)
Fig. 2 Positive proportion of seven biomarkers in HGSC and CCC
patients. CCC patients expressed higher level of HER2 and BRCA1
than HGSC patients (12.6% vs 2.7%, 45.7% vs 27.4%, P = 0.006, 0.007
respectively, Chi-squared test)
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lower expression level in recurrent CCC patients, com-
pared with no recurrent CCC patients (P = 0.023). Inter-
estingly, no similar phenomenon was observed in HGSC
patients. Then we stratified recurrent cases based on the
response to platinum-based chemotherapy, and no signifi-
cant association was observed (Additional file 1: Table S4).
Discussion
Deciphering ovarian CCC molecular expression patterns
is important not only for understanding the pathogenesis
of this rare disease but also for exploring therapeutic op-
tions for patients who are chemotherapeutic resistant. In
this study, we investigated the molecular characterization
of CCC patients compared with HGSC patients on several
actionable drug-based molecular biomarkers. These mo-
lecular biomarkers might be valuable for predicting the
outcome and the response to chemotherapeutic regimens
for CCC, compared with the classical clinicopathological
prognostic factors [17].
EGFR and HER2 are the members of the HER family,
whose EGF signaling pathway is known to play a crucial
role in tumor initiation, progression and metastasis. In
this study, EGFR and HER2 protein were more fre-
quently expressed in CCC patients than in HGSC pa-
tients (35.9% vs 27.4%, 12.6% vs 2.7%, respectively).
Besides, Aikou Okamoto et al. observed a gene amplifi-
cation of EGFR in CCCs and it was related with endo-
metriosis [18]. In line with this, our finding showed that
there was 44.4% CCC patients with endometriosis
expressed high level of EGFR, while only 8.3% patients
with endometriosis in HGSC have high expression of
EGFR (Fig. 4, P = 0.049). Tan et al. also reported that
HER2 gene amplification and protein overexpression
were observed in 14% of CCCs through hierarchical
cluster analysis [19]. However, Friedlander ML et al.
demonstrated that only 2.6% of pure CCCs expressed
high level of HER2 protein by IHC tests, but 9.4% of
CCCs showed HER2 gene amplification by fluorescent
in situ hybridization (FISH) tests [20]. These inconsist-
ent results might be caused by differences in the scale of
cohorts and criteria of the cut-off value for positive
cases. Moreover, evidence on the prognostic value of
EGFR and HER2 with respect to survival is still incon-
clusive in ovarian cancer [21]. We observed a favorable
Table 3 Association of the expression level of molecular biomarkers with PFS/OS
Molecular biomarkers High-grade serous carcinoma Clear cell carcinoma Pe value
Cases (%) P(OS) P(PFS) Cases (%) P(OS) P(PFS)
EGFR 113(100) 0.017 0.042 92(100) 0.012 0.267 0.195
Negative 82(72.6) 59(64.1)
Positive 31(27.4) 33(35.9)
HER2 113(100) 0.938 0.475 95(100) 0.001 0.200 0.006
Negative 110(97.3) 83(87.4)
Positive 3(2.7) 12(12.6)
PTEN 113(100) 0.323 0.397 93(100) 0.160 0.061 0.716
Negative 99(87.6) 83(89.2)
Positive 14(12.4) 10(10.8)
AURKA 113(100) 0.006 0.382 95(100) 0.022 0.035 0.582
Negative 72(63.7) 57(60.0)
Positive 41(36.3) 38(40.0)
BRCA1 113(100) 0.017 0.032 92(100) 0.823 0.424 0.007
Negative 82(72.6) 50(54.3)
Positive 31(27.4) 42(45.7)
BRCA2 113(100) 0.743 0.500 94(100) 0.466 0.929 0.054
Negative 101(89.4) 75(79.8)
Positive 12(10.6) 19(20.2)
PD-L1 113(100) 0.037 0.159 95(100) 0.773 0.425 0.064
Negative 99(88.4) 75(78.9)
Positive 13(11.6) 20 (21.1)
A total of 113 cases of HGSC and 96 cases of CCC have both primary tumor immunohistochemistry results and survival information. However, the total number
for each antibody does not add to up 96 in CCC group
aChi-squared tests were performed for the difference of positive rates between HGSC and CCC groups
Bold value denotes P with statistical significance
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Fig. 3 Kaplan–Meier survival curves based on immunohistochemistry results. Five of seven biomarkers (EGFR, HER2, AURKA, BRCA1, PD-L1) are
significantly associated with overall survival (OS) in HGSC and/or CCC patients
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prognostic value of EGFR in CCCs and a reverse prog-
nostic value in HGSCs. This contrasting result could be
explained by the phenomenon that the positive rate of
EGFR of CCC patients in early stage (I + II) was much
higher than of HGSC patients in early stage (39.7% vs
17.7%, Additional file 1: Table S2A and B), which im-
plied that EGFR might play a favorable part in the earlier
progression of CCC. And previous studies either focused
on stage III/IV ovarian patients, or performed IHC assay
in a smaller sample size of CCC because of the rarity of
this subtype, which might cause bias. In addition, Wang
et al. showed that high expression of EGFR in tumor
stroma, rather than in tumor cells, correlates with aggres-
sive clinical features in epithelial ovarian cancer, and is an
independent prognostic factor [22]. This complexity of the
role of EGF signaling pathway in ovarian cancer explained,
at least in part, why several clinical trials performed on
patients with positive EGFR or HER2 immunostaining
or genetic changes did not show satisfying response to
HER-targeted therapy [23–25].
Table 4 Multivariate cox analyses of biomarkers and clinical factors with OS
High-grade serous carcinoma Clear cell carcinoma
Factors Hazard Ratio (95% CI) HGSC P Hazard Ratio (95% CI) CCC P
Stage
Early(I + II) 1.000 1.000
Late(III + IV) 3.320(0.965–11.427) 0.057 9.703(2.588–36.381) 0.001
Residual tumor
< 1 cm 1.000 1.000
> 1 cm 1.367(0.560–3.339) 0.492 1.400(0.244–8.032) 0.706
Ascites
No 1.000 1.000
Yes 0.994(0.293–3.373) 0.993 2.587(0.848–7.890) 0.095
Chemotherapeutic response
Sensitive 1.000 1.000
Resistant 3.803(2.170–6.664) 0.000 3.562(1.063–11.936) 0.040
EGFR
Negative 1.000 1.000
Positive 1.244(0.653–2.370) 0.507 0.044(0.003–0628) 0.021
HER2
Negative 1.000 1.000
Positive 1.277(0.299–5.456) 0.741 7.948(1.745–36.208) 0.007
PTEN
Negative 1.000 1.000
Positive 0.696(0.257–1.880) 0.474 4.475(0.825–24.274) 0.082
AURKA
Negative 1.000 1.000
Positive 2.082(1.162–3.730) 0.014 1.763(0.616–5.044) 0.291
BRCA1
Negative 1.000 1.000
Positive 0.433(0.211–0.885) 0.022 1.934(0.653–5.738) 0.235
BRCA2
Negative 1.000 1.000
Positive 1.671(0.755–3.701) 0.206 1.258(0.352–4.493) 0.723
PD-L1
Negative 1.000 1.000
Positive 0.520(0.182–1.487) 0.222 1.157(0.387–3.456) 0.794
CI confidence interval
Bold value denotes P with statistical significance
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TCGA (The Cancer Genome Atlas) analyses showed
that the BRCA1 and BRCA2 mutations in 22% of the
high-grade serous ovarian cancer samples triggered a
wide range of aberrations in DNA damage repair path-
ways, such as homologous repair pathway [26]. Patients
with germline BRCA mutation gained great clinical
benefit from using PARP (Poly ADP-ribose polymerase)
inhibitors, olaparib for instance, in clinical trials [27].
Beyond this, Konstantinopoulos et al. found that BRCA-
ness profile (patients with sporadic cancers that have a
BRCAness phenotype, characterized by defective homolo-
gous repair) correlates with responsiveness to platinum
and PARP inhibitors and identifies a subset of patients
with improved outcome [28–30]. Our analysis revealed
that loss of BRCA1 expression was more frequently
occurred in HGSC patients than in CCC patients,
predicting a shorter overall survival time (P = 0.017),
which implied potential benefits of PARP inhibitors.
However, it is suggested a deeper exploration of the
relationship between genetic changes and protein ex-
pression of BRCA1/2 in sporadic ovarian cancer. In
addition to somatic BRCA1/2 mutation, PTEN loss
may be a common contributing event causing homolo-
gous repair dysfunction. Previous studies have shown that
ovarian CCC often exhibit genetic alterations of PTEN in
5% CCC patients [31], and preclinical researched showed
that ovarian cell lines with PTEN mutation were more
Fig. 4 Overexpression of EGFR was more frequently observed in CCC
patients with endometriosis than in HGSC patients (44.4% vs 8.3%,
P = 0.049, Chi-squared test)
Table 5 Correlation of molecular biomarker expression and chemotherapeutic response
Molecular biomarkers HGSC CCC
Platinum sensitive (%) aPlatinum resistant (%) HGSCP Platinum sensitive (%) aPlatinum resistant (%) CCC P
EGFR 0.365 0.129
Negative 58(75.3) 20(66.7) 36(58.1) 17(77.3)
Positive 19(24.7) 10(33.3) 26(41.9) 5(22.7)
HER2 1.000 0.725
Negative 75(97.4) 29(96.7) 56(87.5) 19(82.6)
Positive 2(2.6) 1(3.3) 8(12.5) 4(17.4)
PTEN 0.530 0.679
Negative 68(88.3) 25(83.3) 58(92.1) 21(87.5)
Positive 9(11.7) 5(16.7) 5(7.9) 3(12.5)
AURKA 0.505 0.042
Negative 49(63.6) 17(56.7) 42(65.6) 10(41.7)
Positive 28(36.3) 13(43.3) 22(34.4) 14(58.3)
BRCA1 0.584 0.848
Negative 55(71.4) 23(76.7) 35(56.5) 13(54.2)
Positive 22(28.6) 7(23.3) 27(43.5) 11(45.8)
BRCA2 1.000 0.542
Negative 68(88.3) 27(90.0) 50(80.6) 21(87.5)
Positive 9(11.7) 3(10.0) 12(19.4) 3(12.5)
PD-L1 0.502 0.028
Negative 66(86.8) 28(93.3) 56(87.5) 15(65.2)
Positive 10(13.2) 2(6.7) 8(12.5) 8(34.8)
There are 107 cases of HGSC and 88 cases of CCC having both primary tumor immunohistochemistry results and information of chemotherapy. However, the total
number for each antibody does not add to up 107 and 88, respectively
aInterval time <6 months from completion of last platinum-based chemotherapy to disease recurrence
Bold value denotes P with statistical significance
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sensitive to PARP inhibitors [32]. In the present study, we
observed a much higher level of PTEN loss in both of
HGSCs (87.6%) and CCCs (89.2%), compared with previ-
ous studies [17, 20]. This might be due to the different
efficacy of the antibodies used in IHC test. According to
our analyses (Additional file 1: Table S2A and B), CCCs
have a higher rate of PTEN silence in early stage than
HGSCs (92.0% vs 70.5%, respectively). However, targeting
PTEN only is not enough due to tumors with ARID1A
mutation also frequently harbor PTEN or PIK3CA muta-
tion in CCC [33, 34]. Therefore, it is worth trying to use
PARP inhibitors for patients with sporadic cancers who
lose BRCA or PTEN expression, as well as in combination
with other target drugs if necessary.
Aurora kinase A (AURKA) is involved with centro-
some function, mitotic entry and spindle assembly in
cells [35]. Recently AURKA has been extensively investi-
gated in different neoplasms, including breast, ovarian,
colon, liver, pancreas, bladder, and gastric carcinomas
[36]. Even if the molecular mechanism of AURKA is com-
plex [37, 38], several researches implied that AURKA pro-
tein expression is strongly linked with poor patient
outcome and aggressive disease characteristics of ovarian
cancer [39, 40]. Consistently, we found the same effects of
AURKA in CCC patients that both of the overall survival
time and progression-free time were shortened in CCCs
with high expression level of AURKA (P < 0.05, Table 3).
In addition, overexpression of AURKA also had a relation-
ship with platinum-based chemotherapeutic resistance in
CCC patients, suggesting that targeted at AURKA might
provide a promising therapeutic option. Most recently,
ENMD-2076, acting by blocking AURKA and tyrosine
kinase enzymes from working and stopping new blood
vessels from growing, is in phase II clinical trial designed
specifically for CCC patients (ClinicalTrials.gov number,
NCT01914510). The result will be posted in 2018.
Surgery and chemotherapy is the mainstay of ovarian
cancer treatment. However, with the development of im-
munology, immunotherapy represents a rational and alter-
native approach for ovarian patients, especially for those
who have recurrent and/or chemotherapeutic resistant
diseases [41–43]. Programmed death 1 (PD-1) and its
ligand PD-L1 play a crucial role in the inhibition of T
cell-mediated immune response. Binding of PD-L1 to
PD-1 causes the exhaustion of effector T cells and im-
mune escape of tumor cells, leading to poor prognostic
outcome. Previous studies have shown that overexpres-
sion of PD-L1 in cancers such as gastric cancer, hepatocel-
lular carcinoma, renal cell carcinoma and esophageal
cancer, pancreatic cancer and bladder cancer is related to
poor prognosis. However, PD-L1 expression correlates
with better clinical outcomes in breast cancer and Merkel
cell carcinoma [44]. The prognostic value of PD-L1 in
ovarian cancer is controversial [45, 46]. A recent study of
490 EOC cases revealed that PD-L1 had a positive associ-
ation with survival in high-grade serous subtype rather
than clear cell subtype [45]. Accordingly, our results also
showed that PD-L1 expression was correlated with a fa-
vorable prognosis of HGSC patients (Fig. 2, P = 0.037),
which might be caused by an immunological stalemate
that activation of T cells triggered a negative feedback in
the microenvironment around tumor cells. Another study
reported by Friedlander ML et al. showed that only 7.4%
of CCC cases have aberrant PD-L1 overexpression through
IHC method. However, the sample size in Friedlander’s
study is too small (n = 27) and no detailed clinical informa-
tion to further analyze [20]. By performing analysis on a
larger scale (n = 96), we found that there was no significant
correlation between PD-L1 expression and prognosis in
CCC patients, but higher expression of PD-L1 was ob-
served in this subtype than in HGSC (21.1% vs 11.6%,
respectively). And by combining with the analysis of
chemotherapeutic response, it is revealed that CCC pa-
tients with high expression level of PD-L1 tend to be more
resistant to platinum-based chemotherapy (P = 0.028),
which suggested that PD-L1 might play a part in the che-
moresistance of CCC patients.
It is true that different studies may probably draw dif-
ferent conclusions from TMA immunohistochemistry
(IHC) because of various reasons, such as the efficacy of
antibodies, intra-tumor heterogeneity, criteria of the cut-
off value for positive cores and sufficient follow-up time
of patients. Although we have tried our best to balance
these factors, there are still some limitations in our
study. Firstly, since there being no uniform interpreta-
tions for IHC scoring and analyses, we used the same
cut-off value for all antibodies, which might not be opti-
mal for each marker. Secondly, we did not perform cor-
rection for multiple comparisons in some of our analyses.
While IHC assay could only detect protein expression
changes, DNA sequencing is still needed to further inves-
tigate genes status for these molecular biomarkers. Indeed,
our work is exploratory and descriptive, we would try to
solve these problems and perform larger cohort studies
combined with genomic changes in the next future.
Conclusions
Ovarian clear cell carcinoma showed a markedly differ-
ent biomarker protein expression map from high-grade
serous carcinoma. Expression level of HER2 and PD-L1
were higher in CCC patients, compared with HGSC.
Besides, overexpression of AURKA and PD-L1 signifi-
cantly associated with chemoresistance in CCC. All
these differences suggested newly designed clinical
trials of candidate target drugs for this rare subtype,
and deserved further investigation of potential molecu-
lar mechanisms.
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